Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Hikma Pharmaceuticals PLC (GB:HIK)
LSE:HIK
RESEARCH TOOLSreports
Holding GB:HIK?
Track your performance easily
HIK Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range1,711.00p - 2,165.00p
Previous Close1,872p
Volume58.20K
Average Volume (3M)404.45K
Market Cap
£4.15B
Enterprise Value4.94B
Total Cash (Recent Filing)$205.00M
Total Debt (Recent Filing)$1.19B
Price to Earnings (P/E)18.4
Beta0.87
Next Earnings
Feb 20, 2025EPS EstimateN/A
Last Dividend Ex-Date
Aug 15, 2024Dividend Yield3.36%
Share Statistics
EPS (TTM)1.02
Shares Outstanding221,886,453
10 Day Avg. Volume768,613
30 Day Avg. Volume404,452
Standard Deviation0.08
R-Squared0.03
Alpha0.00254
Financial Highlights & Ratios
Price to Book (P/B)179.13
Price to Sales (P/S)1.81
Price to Cash Flow (P/CF)13.80
P/FCF Ratio19.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.55
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
2,300.00pPrice Target Upside17.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Hikma Pharmaceuticals News
PremiumCompany Announcements
Hikma Pharmaceuticals Reappoints PwC as Auditor
PremiumCompany Announcements
Hikma Pharmaceuticals Projects Strong Growth for 2024
PremiumCompany Announcements
Hikma Pharmaceuticals Faces Shareholder Opposition on Buyback Waiver
PremiumCompany Announcements
Hikma Executives Invest in Company Shares
PremiumCompany Announcements
Hikma Pharmaceuticals Expands with Xellia Acquisition
PremiumCompany Announcements
Hikma Executive Sells Shares Worth £888.5K
PremiumCompany Announcements
Hikma Pharmaceuticals Reports Strong H1 GrowthOptions Prices
Currently, No data available
---
Ownership Overview
7.66% Insiders
5.03% Mutual Funds
― Other Institutional Investors
78.57% Public Companies and
Individual Investors
HIK FAQ
What was Hikma Pharmaceuticals PLC’s price range in the past 12 months?
Hikma Pharmaceuticals PLC lowest share price was 1711.00p and its highest was 2165.00p in the past 12 months.
What is Hikma Pharmaceuticals PLC’s market cap?
Currently, no data Available
When is Hikma Pharmaceuticals PLC’s upcoming earnings report date?
Hikma Pharmaceuticals PLC’s upcoming earnings report date is Feb 20, 2025 which is in 89 days.
How were Hikma Pharmaceuticals PLC’s earnings last quarter?
Hikma Pharmaceuticals PLC released its earnings results on Aug 08, 2024. The company reported 1.001p earnings per share for the quarter, beating the consensus estimate of N/A by 1.001p.
Is Hikma Pharmaceuticals PLC overvalued?
According to Wall Street analysts Hikma Pharmaceuticals PLC’s price is currently Undervalued.
Does Hikma Pharmaceuticals PLC pay dividends?
Hikma Pharmaceuticals PLC pays a Annually dividend of 25.17p which represents an annual dividend yield of 3.36%. See more information on Hikma Pharmaceuticals PLC dividends here
What is Hikma Pharmaceuticals PLC’s EPS estimate?
Hikma Pharmaceuticals PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hikma Pharmaceuticals PLC have?
Hikma Pharmaceuticals PLC has 221,886,460 shares outstanding.
What happened to Hikma Pharmaceuticals PLC’s price movement after its last earnings report?
Hikma Pharmaceuticals PLC reported an EPS of 1.001p in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 8.261%.
Which hedge fund is a major shareholder of Hikma Pharmaceuticals PLC?
Currently, no hedge funds are holding shares in GB:HIK
---
Hikma Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
2,300.00p (17.14% Upside)
2,300.00p (17.14% Upside)
Blogger Sentiment
Bullish
GB:HIK Sentiment 100%
Sector Average 72%
Sector Average 72%
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.89%
12-Months-Change
Fundamentals
Return on Equity
12.79%
Trailing 12-Months
Asset Growth
5.54%
Trailing 12-Months
Company Description
Hikma Pharmaceuticals PLC
Founded in the Middle East and with headquarters in London, Hikma manufactures generic and in-licensed pharmaceuticals. The firm operates in three segments: injectables, generics, branded, and other, which comprise most of the company's revenue at about 41%, 33%, and 26%, respectively. About 62%, 33%, and 6% of Hikma's sales are based in the U.S., Middle East, North Africa, and Europe, and Other.
---
HIK Stock 12 Month Forecast
Average Price Target
2,300.00p
▲(17.14% Upside)
Technical Analysis
Best Analysts Covering HIK
1 Year
1 Year Success Rate
11/15 ratings generated profit
1 Year Average Return
+6.19%
assigned a buy rating 4 months ago
Copying Peter Verdult's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +6.19% per trade.
---